A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2018
Price : $35 *
At a glance
- Drugs Ibudilast (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- 05 Oct 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 According to a MediciNova media release, that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) will fund this trial. The NIAAA R01 research funding was awarded to Principal Investigator Dr. Lara Ray at the University of California (UCLA) Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute. MediciNova will provide drug supply and regulatory support for the trial.
- 25 Jul 2018 New trial record